Participating Faculty: Economic Evaluation of a Fluocinolone Acetonide Intravitreal Implant for Patients With DME Based on the FAME Study

This supplement to The American Journal of Managed Care describes an economic evaluation of a fluocinolone acetonide (FAc) intravitreal implant for patients with diabetic macular edema (DME). The results show that from both a healthcare and societal perspective, the FAc implant is a costeffective treatment for patients with DME who have received a previous course of a corticosteroid with no clinically significant rise in intraocular pressure.This supplement was sponsored by Alimera Sciences.

Faculty

Antonio Cutino, BA

Vice President

Medical Affairs

Alimera Sciences

Alpharetta, Georgia

Kenneth Green, PhD

Chief Scientific Officer

Alimera Sciences

Alpharetta, Georgia

Robyn Kendall, PGDip, BSc

Health Economist

ICON Commercialization and Outcomes

Vancouver, BC, Canada

Peter T. Moore, MSc

Lead Health Economist

ICON Health Economics and Epidemiology

Sydney, Australia

Christopher Zachary, MBA

Vice President

US Managed Markets

Alimera Sciences

Alpharetta, Georgia

Faculty Disclosures

These faculty report relationships with the following organizations:

Antonio Cutino, BA

Employment and stock ownership: Alimera Sciences

Kenneth Green, PhD

Employment and stock ownership: Alimera Sciences

Peter T. Moore, MSc

Consultant and receipt of payment for involvement in preparation of manuscript: Alimera Sciences

Christopher Zachary, MBA

Employment and stock ownership: Alimera Sciences

Robyn Kendall, PGDip, BSc, reports no relationships or financial interests with any entity that would pose a conflict of interest with the

subject matter of this supplement.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Download PDF: Participating Faculty: Economic Evaluation of a Fluocinolone Acetonide Intravitreal Implant for Patients With DME Based on the FAME Study